KAFADAR, A. Et Al. 2015. Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Patients with Primary Brain Tumors.. Anticancer research , vol.35, no.7 , 3933-42.

KAFADAR, A., KÜÇÜKHÜSEYİN, Ö., TURAN, S., YENILMEZ, E. N., TUNOGLU, S., ZEYBEK, U., ... Kaynar, M. Y.(2015). Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Patients with Primary Brain Tumors.. Anticancer research , vol.35, no.7, 3933-42.

KAFADAR, Ali Et Al. "Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Patients with Primary Brain Tumors.," Anticancer research , vol.35, no.7, 3933-42, 2015

KAFADAR, Ali Et Al. "Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Patients with Primary Brain Tumors.." Anticancer research , vol.35, no.7, pp.3933-42, 2015

KAFADAR, A. Et Al. (2015) . "Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Patients with Primary Brain Tumors.." Anticancer research , vol.35, no.7, pp.3933-42.

@article{article, author={Ali KAFADAR Et Al. }, title={Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Patients with Primary Brain Tumors.}, journal={Anticancer research}, year=2015, pages={3933-42} }